# A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

> **NCT06520098** · PHASE2 · RECRUITING · sponsor: **VA Office of Research and Development** · enrollment: 100 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Ibrutinib, Acalabrutinib, Zanubrutinib

## Key facts

- **NCT ID:** NCT06520098
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2030-06-30
- **Final completion:** 2030-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06520098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06520098, "A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06520098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*